Stability of extemporaneously prepared preservative-free methylphenidate 5 mg/mL intravenous solution.


Journal

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
ISSN: 1535-2900
Titre abrégé: Am J Health Syst Pharm
Pays: England
ID NLM: 9503023

Informations de publication

Date de publication:
18 02 2022
Historique:
pubmed: 18 11 2021
medline: 1 3 2022
entrez: 17 11 2021
Statut: ppublish

Résumé

To advance the implementation of consciousness-promoting therapies in patients with acute disorders of consciousness, the availability of potential therapeutic agents in formulations suitable for administration in hospitalized patients in the presence of complex comorbid conditions is paramount. The purpose of this study is to evaluate the long-term stability of extemporaneously prepared preservative-free methylphenidate hydrochloride (HCl) 5 mg/mL intravenous solution for experimental use. A methylphenidate 5 mg/mL solution was prepared under proper aseptic techniques with Methylphenidate Hydrochloride, USP, powder mixed in sterile water for solution. Methylphenidate HCl 5 mg/mL solution was sterilized by filtration technique under USP <797>-compliant conditions. Samples were stored refrigerated (2-8°C) and analyzed at approximately days 1, 30, 60, 90, 180, and 365. At each time point, chemical and physical stability were evaluated by visual inspection, pH measurement, membrane filtration procedure, turbidometric or photometric technique, and high-performance liquid chromatography analysis. Over the 1-year study period, the samples retained 96.76% to 102.04% of the initial methylphenidate concentration. There was no significant change in the visual appearance, pH level, or particulate matter during the study period. The sterility of samples was maintained and endotoxin levels were undetectable throughout the 1-year stability period. Extemporaneously prepared preservative-free methylphenidate 5 mg/mL intravenous solution was physically and chemically stable at 32, 61, 95, 186, and 365 days when stored in amber glass vials at refrigerated temperatures (2-8°C).

Identifiants

pubmed: 34788364
pii: 6425726
doi: 10.1093/ajhp/zxab420
pmc: PMC9013207
doi:

Substances chimiques

Methylphenidate 207ZZ9QZ49

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

359-363

Subventions

Organisme : NICHD NIH HHS
ID : DP2 HD101400
Pays : United States
Organisme : NIGMS NIH HHS
ID : P01 GM118269
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS109627
Pays : United States

Informations de copyright

© American Society of Health-System Pharmacists 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Neurocrit Care. 2020 Oct;33(2):364-375
pubmed: 32794142
Anesthesiology. 2011 Oct;115(4):791-803
pubmed: 21934407
Curr Neuropharmacol. 2016;14(3):272-81
pubmed: 26951094
Clin Pharmacokinet. 1999 Dec;37(6):457-70
pubmed: 10628897
Neurocrit Care. 2020 Aug;33(1):1-12
pubmed: 32578124
Resuscitation. 2013 Jun;84(6):818-24
pubmed: 23178867
Drugs R D. 2021 Mar;21(1):39-64
pubmed: 33346878
Am J Health Syst Pharm. 2014 Jan 15;71(2):145-66
pubmed: 24375608
Psychopharmacology (Berl). 1978 Sep 15;59(1):75-8
pubmed: 100818
Anesthesiology. 2012 May;116(5):998-1005
pubmed: 22446983
Acta Neurol Scand. 2017 Jan;135(1):100-107
pubmed: 26991608
Chest. 2012 May;141(5):1327-1336
pubmed: 22553267
Neuropsychopharmacology. 2017 Aug;42(9):1766-1775
pubmed: 27874023
J Intensive Care Med. 2020 Nov;35(11):1196-1202
pubmed: 30966863
Arch Phys Med Rehabil. 1998 Sep;79(9):1047-50
pubmed: 9749682

Auteurs

Megan E Barra (ME)

Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.

Brian L Edlow (BL)

Center for Neurotechnology and Neurorecovery, Massachusetts General Hospital, Boston, MA.
Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.

James T Lund (JT)

Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.

Katherine S DeSanctis (KS)

Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.

John Vetrano (J)

Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.

Cherylann Reilly-Tremblay (C)

Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.

Edlyn R Zhang (ER)

Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA.

Yelena G Bodien (YG)

Center for Neurotechnology and Neurorecovery, Massachusetts General Hospital, Boston, MA.
Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.

Emery N Brown (EN)

Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA.
The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Boston, MA, USA.

Ken Solt (K)

Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH